Analytical Performance of the CEDIA® Cyclosporine PLUS Whole Blood Immunoassay

Journal of Analytical Toxicology

Volumn 28, Issue 3, 2004, Pages 204-210

  Butch, Anthony W ^a   Fukuchi, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ACCURACY; ARTICLE; BLOOD; CONTROLLED STUDY; CROSS REACTION; DEVICE; DRUG BLOOD LEVEL; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; EVALUATION; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; IMMUNOASSAY; INTERMETHOD COMPARISON; METABOLITE; PERFORMANCE;

EID: 1842581895     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/28.3.204     Document Type: Article

References (28)

1. B.D. Kahan. Cyclosporine A. N. Engl. J. Med. 321: 1725-1738 (1989).
2. J.F. Borel. Pharmacology of cyclosporin (Sandimmune). Pharmacol. Rev. 42: 260-372 (1989).
3. C.M. Stein, J.J. Murray, and A.J.J. Wood. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin. Chem. 45: 1477-1484 (1999).
4. α/β. Cell. Immunol. 78: 122-129 (1983).
5. S.L. Schreiber and G.R. Crabtree. The mechanism of action of cyclosporin A and FK506. Immunol. Today 13: 136-142 (1992).
6. A. Fahr. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 24: 472-495 (1993).
7. L.M. Shaw, D.W. Holt, P. Keown, R. Venkataramanan, and R.W. Yatscoff. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin. Ther. 21: 1632-1652 (1999).
8. A. Lindholm. Factors influencing the pharmacokinetics of cyclosporine in man. Ther. Drug Monit. 13: 464-477 (1991).
9. L.M. Shaw, R.W. Yatscoff, L.D. Bowers, D.J Freeman, J.R. Jeffery, P.A. Keown, I.J. McGilveray, T.G. Rasano, and P.Y. Wong. Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clin. Chem. 36: 1841-1846 (1990).
10. P.B. Watkins. The role of cytochrome P-450 in cyclosporine metabolism. J. Am. Acad. Dermatol. 23: 1301-1311 (1990).
11. R.W. Yatscoff, T.G. Rosano, and L.D. Bowers. The clinical significance of cyclosporine metabolites. Clin. Biochem. 24: 23-35 (1991).
12. A. Hamwi, A. Salomon, R. Steinbrugger, M. Fritzer-Szekeres, W. Jager, and T. Szekeres. Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods. Am. J. Clin. Pathol. 114: 536-543 (2000).
13. B. Ryffel, B.M.J. Foxwell, M.J. Mihatsch, P. Donatsch, and G. Maurer. Biologic significance of cyclosporine metabolites. Transplant Proc. 20: 575-584 (1988).
14. C.P. Wang, G.T. Burckart, R.J. Ptachcinski, R. Venkataramanan, T. Schwinghammer, T. Hakala T.B. Griffith, R. Hardesty, R. Shadduck, J. Knapp, D.H. Van Thiel, L. Makowka, and T.E. Starzl. Cyclosporine metabolite concentrations in the blood of liver, heart, kidney, and bone marrow transplant patients. Transplant Proc. 20: 591-596 (1988).
15. B.D. Kahan, L.M. Shaw, D. Holt, J. Grevel, and A. Johnston. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin. Chem. 36: 1510-1516 (1990).
16. A. Johnston and D.W. Holt. Therapeutic drug monitoring of immunsuppressant drugs. Br. J. Clin. Pharmacol. 47: 339-350 (1999).
17. A. Hamwi, M. Veitl, G. Manner, K. Ruzicka, C. Schweiger, and T. Szekeres. Evaluation of four automated methods for determination of whole blood cyclosporine concentrations. Am. J. Clin. Pathol. 112: 358-365 (1999).
18. E. Schutz, D. Svinarov, M. Shipkova, P.D. Niedmann, V.W. Armstrong, E. Wieland, and M. Oellerich. Cyclosporin whole blood immunoassays (AxSYM, CEDIA and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin. Chem. 44: 2158-2164 (1998).
19. W. Steimer. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin. Chem. 45: 371-381 (1999).
20. AACC/CAP. "Immunosuppressive drugs". In Participant Summary Report. CS-B, Northfield, IL, 2002.
21. M. Cantarovich, J.S. Barkun, J.I. Tchervenkov, J.G. Besner, L. Aspeslet, and P. Metrakos. Comparison of neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66: 1621-1627 (1998).
22. K. Mahalati, P. Belitsky, I. Sketris, K. West, and R. Panek. Neoral monitoring by simplified sparse sampling area under the concentration curve. Transplantation 68: 55-62 (1999).
23. D. Grant, N. Kneteman, J. Tchervenkov, A. Roy, G. Murphy, A. Tan, L. Hendricks, N. Guilbault, and G. Levy. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 67: 1133-1137 (1999).
24. M. Oellerich and V.W. Armstrong. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther. Drug Monit. 24: 40-46 (2002).
25. L.M. Shaw, R.W. Yatscoff, L.D. Bowers, D.J. Freeman, J.R. Jeffery, P.A. Keown, I.J. McGilverary, T.G. Rosano, and P.Y. Wong. Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clin. Chem. 36: 1841-1846 (1990).
26. M. Oellerich, V.W. Armstrong, B. Kahan, L. Shaw, D.W. Holt, R. Yatscoff, A. Lindholm, P. Halloran, K. Gallicano, K. Wonigeit, E. Schultz, H. Schran, and T. Annesley. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther. Drug Monit. 17: 642-654 (1995).
27. J.M. Tredger, J. Grevel, N. Naoumov, C.M. Steward, A.A. Niven, B. Whiting, and R. Williams. Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. Eur. J. Clin. Pharmacol. 40: 513-519 (1991).
28. W. Steimer. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin. Chem. 45: 371-381 (1999).